Proteomics in hematologic malignancies.
Basic science research in hematology has been determining the functions of gene products using classical approaches that typically involve studying one or a few genes at a time. Proteomics, defined as the study of protein properties on a large scale, provides tools to globally analyze malignant hematologic cells. A major challenge in cancer therapy is the identification of drugs that kill tumor cells while preserving normal cells. Differential display via proteomics enables analysis of direct as well as side-effects of drugs at a molecular level. Proteomics also allows a better understanding of cell signaling pathways involved during apoptosis in hematologic cells. Storing the information in a 2D electrophoresis database enhances the efficiency of proteome research on malignant cells. Finally, the work needed to be carried out on proteomic analysis prior to routine clinical adoption is discussed, and the necessity for multi-institutional collaborations is emphasized.
Caron
Michel
M
Protein Biochemistry and Proteomics Laboratory, Université Paris 13, UFR SMBH, 74, Rue Marcel Cachin, 93017 Bobigny Cedex, France. rm_caron@smbh.univ-paris13.fr
Joubert-Caron
Raymonde
R
D000818:Animals; D017209:Apoptosis; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D019337:Hematologic Neoplasms / Q000737:chemistry / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D020543:Proteome / Q000737:chemistry / Q000378:metabolism*; D040901:Proteomics / Q000379:methods*; D015398:Signal Transduction
D020543:Proteome